ALZN (alzamend.com) Market Value to Book Value Ratio
Alzamend Neuro, Inc. (ALZN) is implementing the LiPRO method for the safe delivery of lithium to the brain to halt Alzheimer's. This chart from the GURU.Markets terminal illustrates the price-to-book value trend, where the current figure stands at 0.94. A production outsourcing model minimizes costs, while strong private support is coupled with cautious expectations from experts.
%20Capitalization%20to%20Book%20Value%20Ratio&width=1200&height=400&colorIndex=0&v=mvrk6wqv.ssk-7as46ww&start=20220704&end=20261028&filename=GURU_Markets_-_ALZN_-_Alzamend-Neuro-Inc._-_Capitalization-to-Book-Value-Ratio "ALZN Alzamend Market Capitalization to Book Value Ratio (07/04/2022 - 10/28/2026) | 👁️GURU.Markets👁️")
Financial and market metric breakdowns for Alzamend Neuro, Inc. (ALZN)
- price and consensus price forecast:
- market capitalization data:
- book capitalization data:
- debt and liquidity data:
Initial company analysis:Alzamend Neuro Inc. - ALZN
This ratio compares the market value of Alzamend Neuro, Inc. (ALZN) to its net assets, determining the degree of asset overvaluation. For a company whose clinical trial costs are growing faster than revenues, this metric reflects market optimism regarding future discoveries. The current P/B ratio of Alzamend Neuro, Inc. (ALZN) stands at 0.94, capturing the real-time investor consensus. The trend for this indicator reveals hidden phases of business cooling. A high value signals the risk of overpaying for capital.
Direct competitors
Market Value to Book Value Ratio Biogen Inc.|NBIX (neurocrine.com) - Capitalization to Book Value Ratio|Market Value to Book Value Ratio Regencell Bioscience Holdings Limited (RGC)|Capitalization to Book Value Ratio Axsome|ACADIA Pharmaceuticals Inc - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Xenon Corp XENE|Market Cap to Net Assets Ratio VKTX (Viking Therapeutics)|supernus.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Catalyst Pharmaceuticals, Inc. (CPRX)|DNLI: Market Value to Book Value|Market Value to Book Value Ratio HRMY|Biohaven Corp (BHVN) - Market-to-Book Ratio|AMLX (Amylyx Pharmaceuticals) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio TRVI|Market Value to Book Value Ratio Praxis Precision Medicines, Inc. (PRAX)|Market Value to Book Value Ratio Anavex AVXL|CeriBell Corp (CBLL) - Market Cap to Net Assets Ratio|Market Capitalization to Net Assets Prothena PRTA|Alector Therapeutics - Market Capitalization to Book Value Ratio|ANNX: Market Capitalization to Book Value Ratio|OMER (omeros.com) - Market Value to Book Value Ratio|Neurogene Inc (NGNE) - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio ACIU (AC Immune Corp)|Market-to-Book Ratio VYGR|Market Value to Book Value Ratio Neumora Therapeutics NMRA|Capitalization to Book Value Ratio scilexholding.com (SCLX)|TVGN - Market Capitalization to Book Value Ratio|ACOG - Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio Cognition Therapeutics, Inc. (CGTX)|IKT: Market Value to Book Value|Market Value to Book Value Ratio Cassava Sciences, Inc.|Assertio (ASRT) - Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio COYA (Coya Therapeutics Inc)|Market-to-Book Ratio VistaGen Therapeutics Inc (VTGN)|Market Cap to Net Assets Ratio OVID|Market Capitalization to Book Value Ratio ABOS (Acumen Pharmaceuticals, Inc)|Market Value to Book Value Ratio CervoMed Inc.|Alterity Therapeutics Ltd. - Market Value to Book Value|CLNN (Clene Nanomedicine) - Market Value to Book Value Ratio|PepGen Inc. (PEPG) - Market-to-Book Ratio|Market Cap to Net Assets Ratio Jupiter Neurosciences JUNS|Relmada Corp (RLMD) - Market Value to Book Value|ANVS: Market Capitalization to Book Value Ratio|Market Capitalization to Book Value GRCE|Market Value to Book Value Ratio Firefly Neuroscience AIFF|Capitalization to Book Value Ratio anewmeds.com (KLTO)|NeuroSense Therapeutics Ltd. - Market Capitalization to Book Value Ratio|RVPH - Market Cap to Net Assets Ratio|Market Cap to Net Assets Ratio MTVA (MetaVia, Inc.)|NRXS - Market Capitalization to Book Value|HSDT: Market Capitalization to Book Value Ratio|PASG (Passage Bio) - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Neuphoria Therapeutics, Inc.|Market Value to Book Value Ratio Minerva (NERV)|ATHA - Market Cap to Net Assets Ratio|Market Capitalization to Net Assets ADXN (addextherapeutics.com)|CYCN - Market Value to Book Value Ratio|Protagenic Therapeutics Inc. - Capitalization to Book Value Ratio|Pasithea (KTTA) - Market Value to Book Value Ratio|CRGT - Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio ATXI|Market-to-Book Ratio brainstorm-cell.com|CARA (Cara Therapeutics) - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio CHRO|Eliem Therapeutics (ELYM) - Market Value to Book Value Ratio|Market Value to Book Value ITCI (intracellulartherapies.com)|LBPH: Market Value to Book Value Ratio|Market-to-Book Ratio marinuspharma.com MRNS|NKGen Biotech - Market Capitalization to Book Value Ratio|NRBO: Market Capitalization to Book Value Ratio|Sage Therapeutics, Inc (SAGE) - Market Value to Book Value Ratio|Market Value to Book Value Ratio Synaptogenix, Inc|Market Cap to Net Assets Ratio Trevena, Inc. TRVN|Market Capitalization to Net Assets Vigil Neuro|Market Capitalization to Book Value Ratio WENA|Market Capitalization to Book Value Ratio CERE (Cerevel Therapeutics Inc)